Gold-Nano Blog / Gold Nanoparticle Cancer Research Report #13`
Originally Posted on 12/19/2019 @ 3:56 pm EST
by Steven Warrenfeltz
Subscribe to this Blog
It's been almost a year since a Gold Nanoparticle Cancer Research Report (GNPCRR) has been posted.
Why? because many of the pages of this bullion guide required updating.
The Free Bullion Investment Guide is a little unusual to other guides because it is not only is for individuals interested in physical precious metals bullion.
This guide also advocates for Gold Nanoparticle Cancer Research, and it gives to individuals who are battling cancer through donations to the Angel of Healing Cancer Fund.
Gold Nanoparticle Cancer Research is a non-invasive cancer treatment that kills cancer without harmful side-effects.
In this report, you'll find summaries of the most promising and compelling studies from the past year in regards to gold nanoparticle medical research.
Below is a glimpse into what you'll find in this report :
Dr. Naomi Halas of Rice University has been studying the properties of gold nanoparticles for nearly thirty years.
In November of 2018, Dr. Naomi Halas answered a few questions for a blog post on this site, see it here.
In one of Dr. Halas's answers, she stated that some of her research was currently in human clinical trials.
The research revolved around using gold nanoshells to ablate tumors from a man's prostate.
Nanospectra Biosciences is a company that is providing the nanoshells for the clinical trials; Nanospectra was founded by Dr. Naomi Halas and Jennifer West, a bio-engineer at Duke University.
The human clinical trials are being conducted by Dr. Rastinehad of Mt. Sinai Hospital in New York, and by Steven E. Canfield of UT Health in Houston, TX.
In August of 2019, the preliminary results were reported as follows:
The pilot device study reports effectiveness and safety data from Mt. Sinai’s first 16 enrolled subjects diagnosed with localized, low to intermediate risk prostate cancer.
After GSN infusion and targeted laser ablation, patients underwent MRI of the prostate at 48 – 72 hours, followed by post-procedure mpMRI/US targeted fusion biopsies at three and 12 months, as well as a standard 12-core systematic biopsy at 12 months.
GSN-mediated focal laser ablation was successfully achieved in 94% (15 of 16) patients.
At the one-year study endpoint, 87.5% (14/16 lesions) were negative for tumor as confirmed by pathology and considered successful treatment outcomes.
Proceedings of the National Academy of Sciences (PNAS)
Furthermore, Dr. Rastinehad of Mt. Sinai Hospital expressed his feelings about the study in the statement below:
“The early results are very encouraging and with feasibility study enrollment now complete we anticipate publishing results at the initial three month endpoint for mpMRI targeted fusion biopsies for the entire 45 subject population early next year.” (2020)
Learn more about this study by following one the two links below:
When most cancer therapies are given to a patient, the drugs that are given attack all of the patient's cells because there is no way for the drug to distinguish a healthy cell from a cancerous one.
However, in this study, Havard Medical researchers have found a way around this problem.
Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a multifunctional gold-nano vehicle with enhanced drug loading and delivery efficiency capabilities.
In addition, the gold nano-vehicles proved to show effective drug delivery efficiency by accumulating at the tumor after i.v. injection in mice, affecting only the cancer cells, not healthy cells.
The triple-drug loaded nano-vehicle delivered its payload to breast cancer so successfully, in mice, that it suppressed the cancer cells by 94% and 87% at total dosages of 5 and 2.5 mg/kg, respectively, through synergy.
Furthermore, the nano-vehicles possess the photothermal properties of nano-gold, which significantly inhibit multi-drug resistance with the use of near-infrared laser irradiation.
Mingtan Hai, a visiting professor at SEAS and co-author of the study said the following about the findings in the research.
“We can use these hybrid nano-vehicles to deliver a new combination of anticancer drugs in mice through intravenous injection and see remarkable effectiveness against breast tumors.”
“This work enables the use of previously undeliverable compounds in cancer therapy and forms a foundation for further development in a broad range of biomedical applications.”
- Harvard John A. Paulson School of Engineering and Applied Sciences
Although this research study is not about cancer, it does offer you a glimpse into how science is using Gold Nanoparticles to make CRISPR more efficient.
'CRISPR' stands for (Clustered Regularly Interspaced Short Palindromic Repeats) it is a genome-editing tool that is centered on splicing DNA.
In this next study, a team of Fred Hutchinson researchers improves the delivery of CRISPR with Gold Nanoparticles to edit genes related to HIV and sickle cell anemia.
CRISPR-Cas9 has had lots of good results in several in the lab controlled research studies, however, one big issue with CRISPR is getting it to its expected destination in a living specimen.
Furthermore, researchers have found that the longer the CRISPR-Cas9 DNA-editing-tool is in the body, it becomes a threat to the body because it could make unwanted 'edits.'
In this new study, researchers loaded gold nanoparticles with the CRISPR gene-editing tool. The gold nanoparticles then delivered and deposited the gene-editing tool into blood stem cells.
After CRISPR's delivery was made it altered genes related to HIV and certain blood disorders, researchers said that "it’s a promising step toward addressing CRISPR’s critical delivery problems."
Senior scientist Dr. Jennifer Adair of Fred Hutchenson stated the following about using gold nanoparticles for the delivery of CRISPR.
"As efficient couriers, they (gold nanoparticles) could reduce the need for engineered viruses and specialized research centers. And that could help make these emerging, high-tech treatments accessible and affordable."
“Gene therapy has a lot of potential across many diseases, but the process we have right now is just not feasible in every place in the world.”
“We want to end up delivering gene therapy in a syringe. This gold nanoparticle represents the first possibility we have to do that for blood stem cells.”
- Dr. Jennifer Adair of Fred Hutchenson
Malignant pleural mesothelioma (MPM) is a rare but very aggressive form of cancer.
Pemetrexed (Pe) is one of the few chemotherapy drugs that are used to fight the disease, even though its effectiveness is limited.
In this study, researchers in Italy used gold nanoparticles to help Pemetrexed (Pe) to be more effective at stopping this rare form of cancer.
Researchers found that cell viability and mobility of cancer cells were reduced when gold nanoparticles were administered with Pemetrexed (Pe).
Below are notes taken from the researcher's experiments, they found that gold nanoparticles greatly enhanced the chemo drug's effectiveness:
- Dove Press
The study concluded the following about the results of the study.
- Dove Press
The two links can provide you with more information about the findings of this research:
In this last study, researchers from the University of Delaware devised an effective way to fight triple-negative breast cancer.
Triple negative breast cancer is a form of breast cancer that accounts for 10 to 20 percent of patients.
University of Delaware researchers Emily Day and Joel Rosenthal have combined two minimally invasive therapies to become a new powerful weapon against this type of breast cancer.
The short video below offers you an animated and informative explanation of Dr. Day and Rosenthal's research.
Please help this guide spread the word about Gold Nanoparticle Medical/Cancer Research by forwarding this blog post to a friend, or a subject related website / forum.
Thank You for your Time.
Take Care & God Bless,